What the Spiritual Caregiver Should Know While Dealing with Survivors of Ethnic Violence
نویسندگان
چکیده
منابع مشابه
What every pediatrician should know about liver transplantation
Liver transplantation is the treatment of choice for children with end-stage liver disease. Improvement in outcomes (allograft and patient survival) has led to widespread use of pediatric LT worldwide. This success is due to improvement in patient selection, transplant surgery, anesthesia/postoperative care and immunosuppression management. This review will focus on different aspects of LT whi...
متن کاملWhat Clinicians Should Know
Case presentation: A 36-year-old nonsmoking, normotensive South Asian man presented to the emergency department of a community hospital with retrosternal chest pain of 60 minutes’ duration. His 12-lead ECG demonstrated 10 mm of STsegment elevation in leads V2 through V6, and he received fibrinolytic therapy within 90 minutes of symptom onset. His pain resolved, but his ST segments only partiall...
متن کاملwhat should we know in bipps
cushing’s syndrome is a rare endocrine disease characterized by hypercortisolemia caused by excess acth secreted by the pituitary. distinguishing pituitary sources from the ectopic sources of acth is challenging because of the limited accuracy of noninvasive assays. the test that offers the highest sensitivity and specificity is bilateral inferior petrosal sinus sampling (bipss). in patients wi...
متن کاملP-138: What Should We Know about Ethical Problem in ART? A Study of Systematic Review
Background: Advances in medical technology have had major impacts on human reproduction. The development of effective contraceptive methods has reduced unwanted fertility, and the development of a variety of drugs and procedures has, for the first time, permitted women with fertility problems to reasonably expect that they can fulfill their desires to have children. So, The aim of this review a...
متن کاملBiosimilars: what clinicians should know.
Biosimilar medicinal products (biosimilars) have become a reality in the European Union and will soon be available in the United States. Despite an established legal pathway for biosimilars in the European Union since 2005 and increasing and detailed regulatory guidance on data requirements for their development and licensing, many clinicians, particularly oncologists, are reluctant to consider...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Khazar Journal of Humanities and Social Sciences
سال: 2011
ISSN: 2223-2621
DOI: 10.5782/2223-2621.2011.14.3.35